Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22943913 | 1.00 | HDAC6 (0.49) | HDAC6HDAC1HDAC8ESR1KDM1A | |
| SCHEMBL22943903 | 1.00 | HDAC6 (0.49) | HDAC6HDAC1HDAC8ESR1KDM1A | |
| SCHEMBL22943921 | 1.00 | HDAC6 (0.49) | HDAC6HDAC1HDAC8ESR1KDM1A | |
| SCHEMBL27229874 | 0.86 | PDK1 (0.34) | HDAC6 | |
| SCHEMBL29784646 | 0.85 | KDM4E (0.38) | HDAC6 | |
| SCHEMBL22944096 | 0.79 | HDAC6 (0.59) | HDAC6HDAC1HDAC8 | |
| SCHEMBL22944092 | 0.79 | HDAC6 (0.59) | HDAC6HDAC1HDAC8 | |
| SCHEMBL22943901 | 0.79 | HDAC6 (0.53) | HDAC6HDAC1HDAC8KDM1A | |
| SCHEMBL22943916 | 0.79 | HDAC6 (0.53) | HDAC6HDAC1HDAC8KDM1A | |
| SCHEMBL22943900 | 0.79 | HDAC6 (0.53) | HDAC6HDAC1HDAC8KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528767-B2 | HDAC6 inhibitors and uses thereof | EIKONIZO THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20220281814-A1 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| WO-2021021979-A2 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281814-A1 | HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | HDAC6 1/4885HDAC1 2/4885HDAC8 8/4885 |
| US-12528767-B2 | HDAC6 inhibitors and uses thereof | HDAC6, HDAC1, HDAC11 | HDAC6 1/4885HDAC1 2/4885HDAC8 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.